Jordi Xaus

Vice President of Clinical Portfolio and Innovation

PhD in Biology from the University of Barcelona (1999) in the field of immune response, he completed his scientific training with postdoctoral stays at La Jolla Cancer Research Foundation / The Burnham Institute (San Diego, USA, 1996) and Genentech Inc (San Francisco, USA, 1999-2000).

After a period as Associate Professor of Immunology at the University of Barcelona (2000-2001), he joined Puleva Biotech SA as head of the Immunology area, where among other projects he led the discovery and development of the Hereditum® line of probiotics. In 2007 he joined Palau Pharma SA as Project Manager, where after an internal reorganization in 2012 he was appointed CSO.

In April 2014, he joined Oryzon Genomics as Alliance and Project Manager. He has subsequently held various positions until being appointed Vice President of Clinical Portfolio and Innovation in January 2020.